呼吸系统疾病患儿经盐酸氨溴索注射液治疗后的临床价值分析(1)
[摘要] 目的 呼吸系統疾病患儿经盐酸氨溴索注射液治疗后的临床价值分析。方法 方便选取于2018年11月—2019年11月时间段内该院儿科收治的106例呼吸系统疾病患儿为对象展开研究分析，以随机数字表为划分方案，53例患儿为一组院内接受常规治疗方案+布地奈德喷雾治疗方案(对照组)，剩余53例患儿为一组院内接受常规治疗方案+盐酸氨溴索注射液治疗方案(研究组)，比对分析两组患儿的临床症状消失时间、治疗总有效率以及不良反应发生率。结果 研究组患儿在咳嗽、气喘、咳痰、湿啰音等临床症状方面的消失时间为(4.41±1.21)、(2.51±0.77)、(2.48±0.93)、(4.16±1.13)d均明显短于对照组(7.69±1.97)、(3.99±1.20)、(4.18±1.57)、(6.19±1.51)d，对应数据组间差异有统计学意义(t=10.329、7.557、6.782、7.836，P<0.05);研究组患儿的治疗总有效率(96.23%)、不良反应发生率(9.43%)优于对照组患儿的83.02%、35.85%，组间比较差异有统计学意义(χ2=4.970、10.557，P<0.05)。结论 呼吸系统疾病患儿临床接受盐酸氨溴索注射液治疗，可以在短时间内解除患儿的临床症状，有利于患儿取得较好的治疗效果，同时不良反应较少，可以保证治疗安全性。
[关键词] 呼吸系统疾病;患儿;盐酸氨溴索注射液;临床症状
[中图分类号] R72 [文献标识码] A [文章编号] 1674-0742(2020)09(a)-0097-03
[Abstract] Objective To analyze the clinical value of children with respiratory diseases after treatment with ambroxol hydrochloride injection. Methods The 106 children with respiratory diseases admitted to the hospital's pediatrics department from November 2018 to November 2019 were convenient selected for research and analysis. The random number table was used as the division scheme， and 53 children were a group received conventional treatment program + budesonide spray treatment program (control group)， and the remaining 53 children were a group of hospital received conventional treatment program + ambroxol hydrochloride injection treatment program (study group). The two groups were compared and analyzed. The time for children’s clinical symptoms to disappear， the total effective rate of treatment， and the incidence of adverse reactions. Results The disappearance time of clinical symptoms such as cough， wheezing， sputum and wet rales in the study group were： (4.41±1.21)d， (2.51±0.77)d， (2.48±0.93)d， (4.16±1.13)d were significantly shorter than the control group (7.69±1.97)d，(3.99±1.20)d，(4.18±1.57)d，(6.19±1.51)d， the difference between the corresponding data groups was statistically significant (t=10.329， 7.557， 6.782， 7.836， P<0.05); the total effective rate of treatment of children in the study group (96.23%) ， the incidence of adverse reactions (9.43%) was better than 83.02% and 35.85% of the control group， and the difference between the groups was statistically significant (χ2=4.970， 10.557， P<0.05). Conclusion The clinical treatment of ambroxol hydrochloride injection in children with respiratory diseases can relieve the children's clinical symptoms in a short time， which is beneficial to the children to achieve better treatment results， and at the same time， there are fewer adverse reactions and can ensure the safety of treatment., 百拇医药(肖静静)
[关键词] 呼吸系统疾病;患儿;盐酸氨溴索注射液;临床症状
[中图分类号] R72 [文献标识码] A [文章编号] 1674-0742(2020)09(a)-0097-03
[Abstract] Objective To analyze the clinical value of children with respiratory diseases after treatment with ambroxol hydrochloride injection. Methods The 106 children with respiratory diseases admitted to the hospital's pediatrics department from November 2018 to November 2019 were convenient selected for research and analysis. The random number table was used as the division scheme， and 53 children were a group received conventional treatment program + budesonide spray treatment program (control group)， and the remaining 53 children were a group of hospital received conventional treatment program + ambroxol hydrochloride injection treatment program (study group). The two groups were compared and analyzed. The time for children’s clinical symptoms to disappear， the total effective rate of treatment， and the incidence of adverse reactions. Results The disappearance time of clinical symptoms such as cough， wheezing， sputum and wet rales in the study group were： (4.41±1.21)d， (2.51±0.77)d， (2.48±0.93)d， (4.16±1.13)d were significantly shorter than the control group (7.69±1.97)d，(3.99±1.20)d，(4.18±1.57)d，(6.19±1.51)d， the difference between the corresponding data groups was statistically significant (t=10.329， 7.557， 6.782， 7.836， P<0.05); the total effective rate of treatment of children in the study group (96.23%) ， the incidence of adverse reactions (9.43%) was better than 83.02% and 35.85% of the control group， and the difference between the groups was statistically significant (χ2=4.970， 10.557， P<0.05). Conclusion The clinical treatment of ambroxol hydrochloride injection in children with respiratory diseases can relieve the children's clinical symptoms in a short time， which is beneficial to the children to achieve better treatment results， and at the same time， there are fewer adverse reactions and can ensure the safety of treatment., 百拇医药(肖静静)